CN115038707A - 氮杂卓类稠环化合物及其医药用途 - Google Patents

氮杂卓类稠环化合物及其医药用途 Download PDF

Info

Publication number
CN115038707A
CN115038707A CN202180012105.7A CN202180012105A CN115038707A CN 115038707 A CN115038707 A CN 115038707A CN 202180012105 A CN202180012105 A CN 202180012105A CN 115038707 A CN115038707 A CN 115038707A
Authority
CN
China
Prior art keywords
cycloalkyl
heterocyclyl
alkyl
heteroaryl
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180012105.7A
Other languages
English (en)
Inventor
殷惠军
闫旭
沙汉明
刘国标
王国政
李斌
温俊歌
路嘉伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institutes of Pharmaceutical R&D Co Ltd
Original Assignee
National Institutes of Pharmaceutical R&D Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institutes of Pharmaceutical R&D Co Ltd filed Critical National Institutes of Pharmaceutical R&D Co Ltd
Publication of CN115038707A publication Critical patent/CN115038707A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及氮杂卓类稠环化合物及其医药用途。具体地，本发明涉及通式(I)所示的氮杂卓类稠环化合物，其制备方法，含有其的药物组合物，以及其作为受体相互作用蛋白激酶1(RIP1)抑制剂，用于治疗与RIP1活性相关的疾病的用途。其中通式(I)中的各取代基的定义与说明书中的定义相同。

Description

PCT国内申请，说明书已公开。

Claims (23)

  1. PCT国内申请，权利要求书已公开。
CN202180012105.7A 2020-05-14 2021-05-13 氮杂卓类稠环化合物及其医药用途 Pending CN115038707A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010406690 2020-05-14
CN2020104066906 2020-05-14
PCT/CN2021/093499 WO2021228173A1 (zh) 2020-05-14 2021-05-13 氮杂卓类稠环化合物及其医药用途

Publications (1)

Publication Number Publication Date
CN115038707A true CN115038707A (zh) 2022-09-09

Family

ID=78525342

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180012105.7A Pending CN115038707A (zh) 2020-05-14 2021-05-13 氮杂卓类稠环化合物及其医药用途

Country Status (3)

Country Link
CN (1) CN115038707A (zh)
TW (1) TW202144353A (zh)
WO (1) WO2021228173A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115867557A (zh) * 2021-05-14 2023-03-28 中国医药研究开发中心有限公司 氮杂卓类稠环化合物及其医药用途

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022171110A1 (en) * 2021-02-10 2022-08-18 Zai Lab (Us) Llc Fused tricyclic compounds as rip1-kinase inhibitors and uses thereof
CN117645579A (zh) * 2022-09-02 2024-03-05 科辉智药生物科技(深圳)有限公司 作为ripk1抑制剂的氮杂䓬类稠环化合物及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108431004A (zh) * 2015-10-23 2018-08-21 武田药品工业株式会社 杂环化合物
CN109134448A (zh) * 2018-10-16 2019-01-04 中南大学湘雅医院 杂环化合物及其盐、制备方法、用途和药物
WO2019204537A1 (en) * 2018-04-20 2019-10-24 Genentech, Inc. N-[4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol e-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs)
WO2020001420A1 (zh) * 2018-06-26 2020-01-02 中国科学院上海有机化学研究所 一类细胞坏死抑制剂及其制备方法和用途
CN115867557A (zh) * 2021-05-14 2023-03-28 中国医药研究开发中心有限公司 氮杂卓类稠环化合物及其医药用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108431004A (zh) * 2015-10-23 2018-08-21 武田药品工业株式会社 杂环化合物
WO2019204537A1 (en) * 2018-04-20 2019-10-24 Genentech, Inc. N-[4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol e-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs)
WO2020001420A1 (zh) * 2018-06-26 2020-01-02 中国科学院上海有机化学研究所 一类细胞坏死抑制剂及其制备方法和用途
CN109134448A (zh) * 2018-10-16 2019-01-04 中南大学湘雅医院 杂环化合物及其盐、制备方法、用途和药物
CN115867557A (zh) * 2021-05-14 2023-03-28 中国医药研究开发中心有限公司 氮杂卓类稠环化合物及其医药用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MASATO YOSHIKAWA等: "Discovery of 7-Oxo-2, 4, 5, 7-tetrahydro-6H-pyrazolo[3, 4-c]pyridine Derivatives as Potent, Orally Available, and Brain-Penetrating Receptor Interacting Protein 1 (RIP1) Kinase Inhibitors: Analysis of Structure-Kinetic Relationships", 《J.MED.CHEM.》, vol. 61, no. 6, pages 4 - 5 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115867557A (zh) * 2021-05-14 2023-03-28 中国医药研究开发中心有限公司 氮杂卓类稠环化合物及其医药用途

Also Published As

Publication number Publication date
TW202144353A (zh) 2021-12-01
WO2021228173A1 (zh) 2021-11-18

Similar Documents

Publication Publication Date Title
CN111295384B (zh) 双环类衍生物抑制剂、其制备方法和应用
TW202100532A (zh) 稠合三環化合物
CN110627796B (zh) 含氮杂环类衍生物及其在医药上的应用
CN112368283B (zh) 含二并环类衍生物抑制剂、其制备方法和应用
JP5654715B1 (ja) テトラヒドロイミダゾ［１，５−ｄ］［１，４］オキサゼピン誘導体（ＴＥＴＲＡＨＹＤＲＯＩＭＩＤＡＺＯ［１，５−ｄ］［１，４］ＯＸＡＺＥＰＩＮＥＤＥＲＩＶＡＴＩＶＥ）
WO2020108590A1 (zh) 嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用
KR102418195B1 (ko) Acc 억제제로의 화합물 및 이의 용도
TW202122396A (zh) ＫＲａｓ Ｇ１２Ｄ抑制劑
AU2008292390B2 (en) Polycyclic compound
CN115038707A (zh) 氮杂卓类稠环化合物及其医药用途
AU2022218560B2 (en) Benzoazepine analogs as inhibiting agents for Bruton's tyrosine kinase
CN112272670A (zh) 含二并环类衍生物抑制剂、其制备方法和应用
TWI580679B (zh) 雜芳基並嘧啶類衍生物、其製備方法和用途
HUE028723T2 (en) Piperidin-4-yl azetidine derivatives as JAK-1 inhibitors
CN115605479B (zh) 吡啶酮并嘧啶类衍生物、其制备方法及其在医药上的应用
CN111662284B (zh) 双杂环取代的氧杂螺环衍生物、其制法与医药上的用途
WO2020188467A1 (zh) 作为激酶抑制剂的稠合三环化合物
WO2014090147A1 (zh) 嘧啶类衍生物及其可药用盐、其制备方法及其在医药上的应用
KR20240051948A (ko) 피라졸로피리디논 화합물
TW202309008A (zh) 類ｐｏｌｏ激酶４抑制劑
CN115867557A (zh) 氮杂卓类稠环化合物及其医药用途
CN116969971A (zh) 含氮大环类化合物及其制备方法和医药用途
CN117229295A (zh) 含氮大环类化合物及其制备方法和医药用途
CN112334465B (zh) 三环取代的氧杂螺环衍生物、其制法与医药上的用途
CN108203432B (zh) 吡喃葡萄糖基衍生物及其在医药上的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40072076

Country of ref document: HK